ziprasidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2865 | 146939-27-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 80 | mg | O |
| 40 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.21 mg/mL | Bocci G, Oprea TI, Benet LZ |
| EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 6.36 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 60 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 5.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 3.10 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 5, 2001 | FDA | PFIZER |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dystonia | 1344.29 | 19.55 | 376 | 17796 | 13443 | 63457407 |
| Blood prolactin abnormal | 1336.16 | 19.55 | 280 | 17892 | 2799 | 63468051 |
| Sexual dysfunction | 1331.99 | 19.55 | 297 | 17875 | 4062 | 63466788 |
| Anosognosia | 1093.65 | 19.55 | 239 | 17933 | 2957 | 63467893 |
| Disturbance in social behaviour | 1024.61 | 19.55 | 236 | 17936 | 3757 | 63467093 |
| Sedation | 1012.90 | 19.55 | 390 | 17782 | 38419 | 63432431 |
| Metabolic disorder | 934.55 | 19.55 | 241 | 17931 | 6262 | 63464588 |
| Dyskinesia | 930.15 | 19.55 | 348 | 17824 | 31654 | 63439196 |
| Personality change | 846.24 | 19.55 | 226 | 17946 | 6747 | 63464103 |
| Suicide attempt | 726.33 | 19.55 | 352 | 17820 | 60566 | 63410284 |
| Tardive dyskinesia | 711.92 | 19.55 | 206 | 17966 | 8296 | 63462554 |
| Blood glucose increased | 399.74 | 19.55 | 266 | 17906 | 83490 | 63387360 |
| Extrapyramidal disorder | 398.30 | 19.55 | 148 | 18024 | 13136 | 63457714 |
| Completed suicide | 384.22 | 19.55 | 324 | 17848 | 145349 | 63325501 |
| Akathisia | 357.41 | 19.55 | 124 | 18048 | 9022 | 63461828 |
| Neuroleptic malignant syndrome | 338.40 | 19.55 | 128 | 18044 | 11928 | 63458922 |
| Orthostatic hypertension | 318.53 | 19.55 | 63 | 18109 | 455 | 63470395 |
| Metabolic syndrome | 273.13 | 19.55 | 68 | 18104 | 1520 | 63469330 |
| Parkinsonism | 250.80 | 19.55 | 99 | 18073 | 10340 | 63460510 |
| Electrocardiogram QT prolonged | 198.18 | 19.55 | 152 | 18020 | 59378 | 63411472 |
| Diabetes mellitus | 191.27 | 19.55 | 145 | 18027 | 55665 | 63415185 |
| Insurance issue | 157.41 | 19.55 | 61 | 18111 | 6060 | 63464790 |
| Suicidal ideation | 156.26 | 19.55 | 135 | 18037 | 62286 | 63408564 |
| Psychotic disorder | 137.90 | 19.55 | 88 | 18084 | 25624 | 63445226 |
| Oculogyric crisis | 127.67 | 19.55 | 38 | 18134 | 1683 | 63469167 |
| Impulse-control disorder | 126.73 | 19.55 | 32 | 18140 | 758 | 63470092 |
| Agitation | 119.61 | 19.55 | 114 | 18058 | 59643 | 63411207 |
| Posture abnormal | 112.27 | 19.55 | 37 | 18135 | 2295 | 63468555 |
| Mania | 110.62 | 19.55 | 59 | 18113 | 12308 | 63458542 |
| Blood prolactin increased | 108.49 | 19.55 | 40 | 18132 | 3463 | 63467387 |
| Tremor | 104.59 | 19.55 | 157 | 18015 | 132082 | 63338768 |
| Hallucination, auditory | 103.08 | 19.55 | 57 | 18115 | 12767 | 63458083 |
| Galactorrhoea | 101.85 | 19.55 | 40 | 18132 | 4115 | 63466735 |
| Dyslipidaemia | 94.74 | 19.55 | 45 | 18127 | 7348 | 63463502 |
| Arthralgia | 93.61 | 19.55 | 24 | 18148 | 569686 | 62901164 |
| Obesity | 85.67 | 19.55 | 70 | 18102 | 29882 | 63440968 |
| Substance abuse | 79.68 | 19.55 | 35 | 18137 | 4772 | 63466078 |
| Pain | 79.47 | 19.55 | 58 | 18114 | 740570 | 62730280 |
| Hyperprolactinaemia | 76.53 | 19.55 | 32 | 18140 | 3868 | 63466982 |
| Cardio-respiratory arrest | 76.45 | 19.55 | 90 | 18082 | 59869 | 63410981 |
| Paranoia | 75.38 | 19.55 | 45 | 18127 | 11634 | 63459216 |
| Torsade de pointes | 74.82 | 19.55 | 47 | 18125 | 13304 | 63457546 |
| Respiratory arrest | 74.42 | 19.55 | 67 | 18105 | 32578 | 63438272 |
| Personality change due to a general medical condition | 73.11 | 19.55 | 16 | 18156 | 198 | 63470652 |
| Weight increased | 72.20 | 19.55 | 200 | 17972 | 260592 | 63210258 |
| Coma | 69.74 | 19.55 | 89 | 18083 | 64275 | 63406575 |
| Anxiety | 69.50 | 19.55 | 176 | 17996 | 217365 | 63253485 |
| Intentional overdose | 68.76 | 19.55 | 95 | 18077 | 74057 | 63396793 |
| Depression | 67.01 | 19.55 | 163 | 18009 | 196329 | 63274521 |
| Joint swelling | 63.89 | 19.55 | 9 | 18163 | 327657 | 63143193 |
| Peripheral swelling | 63.57 | 19.55 | 3 | 18169 | 265939 | 63204911 |
| Diarrhoea | 63.43 | 19.55 | 67 | 18105 | 715299 | 62755551 |
| Somnolence | 62.81 | 19.55 | 150 | 18022 | 178535 | 63292315 |
| Adverse drug reaction | 62.04 | 19.55 | 94 | 18078 | 79620 | 63391230 |
| Condition aggravated | 59.49 | 19.55 | 250 | 17922 | 401967 | 63068883 |
| Overdose | 58.18 | 19.55 | 112 | 18060 | 114966 | 63355884 |
| Infusion related reaction | 57.94 | 19.55 | 3 | 18169 | 245518 | 63225332 |
| Delusion | 56.76 | 19.55 | 38 | 18134 | 11979 | 63458871 |
| Pneumonia | 55.40 | 19.55 | 31 | 18141 | 456736 | 63014114 |
| Arthropathy | 54.99 | 19.55 | 3 | 18169 | 234789 | 63236061 |
| Rheumatoid arthritis | 54.39 | 19.55 | 5 | 18167 | 253814 | 63217036 |
| Rapid eye movement sleep behaviour disorder | 51.28 | 19.55 | 13 | 18159 | 313 | 63470537 |
| Catatonia | 50.57 | 19.55 | 25 | 18147 | 4452 | 63466398 |
| Insomnia | 48.93 | 19.55 | 154 | 18018 | 215098 | 63255752 |
| Product use issue | 48.18 | 19.55 | 4 | 18168 | 220516 | 63250334 |
| Distributive shock | 47.32 | 19.55 | 17 | 18155 | 1366 | 63469484 |
| Abnormal behaviour | 46.92 | 19.55 | 43 | 18129 | 21383 | 63449467 |
| Systemic lupus erythematosus | 45.06 | 19.55 | 4 | 18168 | 208914 | 63261936 |
| Cardiac arrest | 44.25 | 19.55 | 88 | 18084 | 92457 | 63378393 |
| Off label use | 43.82 | 19.55 | 79 | 18093 | 674383 | 62796467 |
| Alopecia | 43.72 | 19.55 | 21 | 18151 | 337515 | 63133335 |
| Muscle rigidity | 41.83 | 19.55 | 31 | 18141 | 11469 | 63459381 |
| Psychomotor hyperactivity | 41.63 | 19.55 | 30 | 18142 | 10633 | 63460217 |
| Swelling | 40.74 | 19.55 | 14 | 18158 | 275364 | 63195486 |
| Abdominal discomfort | 40.00 | 19.55 | 21 | 18151 | 320864 | 63149986 |
| Treatment failure | 39.88 | 19.55 | 5 | 18167 | 199038 | 63271812 |
| Blood triglycerides increased | 39.56 | 19.55 | 31 | 18141 | 12457 | 63458393 |
| Drug ineffective | 38.75 | 19.55 | 462 | 17710 | 1044303 | 62426547 |
| Mental disorder | 38.27 | 19.55 | 42 | 18130 | 25877 | 63444973 |
| Nasopharyngitis | 37.48 | 19.55 | 13 | 18159 | 254244 | 63216606 |
| Fatigue | 37.44 | 19.55 | 130 | 18042 | 887898 | 62582952 |
| Aggression | 36.30 | 19.55 | 39 | 18133 | 23459 | 63447391 |
| Symptom recurrence | 36.01 | 19.55 | 15 | 18157 | 1795 | 63469055 |
| General physical health deterioration | 35.96 | 19.55 | 7 | 18165 | 201395 | 63269455 |
| Reduced facial expression | 34.81 | 19.55 | 15 | 18157 | 1951 | 63468899 |
| Sinusitis | 34.43 | 19.55 | 11 | 18161 | 226642 | 63244208 |
| Restlessness | 33.91 | 19.55 | 42 | 18130 | 29411 | 63441439 |
| Toxicity to various agents | 33.63 | 19.55 | 150 | 18022 | 247100 | 63223750 |
| Infection | 33.29 | 19.55 | 12 | 18160 | 229161 | 63241689 |
| Type 2 diabetes mellitus | 33.29 | 19.55 | 63 | 18109 | 63805 | 63407045 |
| Wound | 32.95 | 19.55 | 4 | 18168 | 163259 | 63307591 |
| Maternal exposure during pregnancy | 32.87 | 19.55 | 11 | 18161 | 220051 | 63250799 |
| Swollen tongue | 32.86 | 19.55 | 45 | 18127 | 34755 | 63436095 |
| Cardiac hypertrophy | 32.61 | 19.55 | 12 | 18160 | 1033 | 63469817 |
| Rabbit syndrome | 32.06 | 19.55 | 9 | 18163 | 323 | 63470527 |
| Pyrexia | 31.50 | 19.55 | 54 | 18118 | 470424 | 63000426 |
| Mental status changes | 31.22 | 19.55 | 47 | 18125 | 39552 | 63431298 |
| Cough | 29.88 | 19.55 | 24 | 18148 | 292719 | 63178131 |
| Tachyphrenia | 29.42 | 19.55 | 12 | 18160 | 1362 | 63469488 |
| Pain in extremity | 29.32 | 19.55 | 31 | 18141 | 331455 | 63139395 |
| Seizure | 29.28 | 19.55 | 94 | 18078 | 132540 | 63338310 |
| Product substitution issue | 29.13 | 19.55 | 29 | 18143 | 15967 | 63454883 |
| Cognitive disorder | 29.01 | 19.55 | 55 | 18117 | 55760 | 63415090 |
| Abdominal pain | 28.79 | 19.55 | 25 | 18147 | 293431 | 63177419 |
| Torticollis | 28.49 | 19.55 | 13 | 18159 | 1936 | 63468914 |
| Infarction | 27.63 | 19.55 | 14 | 18158 | 2627 | 63468223 |
| Pericarditis | 27.10 | 19.55 | 3 | 18169 | 131576 | 63339274 |
| Glossodynia | 26.60 | 19.55 | 9 | 18163 | 178867 | 63291983 |
| Back pain | 26.53 | 19.55 | 22 | 18150 | 264123 | 63206727 |
| Drug intolerance | 26.04 | 19.55 | 30 | 18142 | 308631 | 63162219 |
| Echolalia | 25.73 | 19.55 | 7 | 18165 | 223 | 63470627 |
| Thrombocytopenia | 25.45 | 19.55 | 6 | 18166 | 151151 | 63319699 |
| Drug withdrawal syndrome | 25.42 | 19.55 | 35 | 18137 | 27159 | 63443691 |
| Drooling | 25.21 | 19.55 | 15 | 18157 | 3853 | 63466997 |
| Hypersensitivity | 25.17 | 19.55 | 28 | 18144 | 292657 | 63178193 |
| Trismus | 25.15 | 19.55 | 15 | 18157 | 3870 | 63466980 |
| Rhabdomyolysis | 24.96 | 19.55 | 45 | 18127 | 43906 | 63426944 |
| Pruritus | 24.62 | 19.55 | 41 | 18131 | 361412 | 63109438 |
| Posturing | 24.30 | 19.55 | 8 | 18164 | 494 | 63470356 |
| Bruxism | 23.84 | 19.55 | 14 | 18158 | 3511 | 63467339 |
| Headache | 23.81 | 19.55 | 97 | 18075 | 633144 | 62837706 |
| Exposure via ingestion | 23.56 | 19.55 | 13 | 18159 | 2896 | 63467954 |
| Irritability | 22.71 | 19.55 | 36 | 18136 | 31658 | 63439192 |
| Cogwheel rigidity | 22.25 | 19.55 | 11 | 18161 | 1959 | 63468891 |
| Sinus bradycardia | 22.21 | 19.55 | 24 | 18148 | 14527 | 63456323 |
| Haemoglobin decreased | 22.19 | 19.55 | 7 | 18165 | 145478 | 63325372 |
| Withdrawal syndrome | 22.19 | 19.55 | 28 | 18144 | 19969 | 63450881 |
| Blister | 22.16 | 19.55 | 5 | 18167 | 129809 | 63341041 |
| Mobility decreased | 22.07 | 19.55 | 4 | 18168 | 121155 | 63349695 |
| Dyspnoea | 22.02 | 19.55 | 106 | 18066 | 661207 | 62809643 |
| Suicidal behaviour | 21.95 | 19.55 | 12 | 18160 | 2627 | 63468223 |
| Amenorrhoea | 21.90 | 19.55 | 20 | 18152 | 9894 | 63460956 |
| Organ failure | 21.81 | 19.55 | 12 | 18160 | 2659 | 63468191 |
| Malaise | 21.70 | 19.55 | 55 | 18117 | 415899 | 63054951 |
| Shock | 21.63 | 19.55 | 30 | 18142 | 23433 | 63447417 |
| Diabetic coma | 21.51 | 19.55 | 8 | 18164 | 709 | 63470141 |
| Nausea | 21.49 | 19.55 | 150 | 18022 | 854321 | 62616529 |
| Stereotypy | 21.22 | 19.55 | 7 | 18165 | 435 | 63470415 |
| Anaemia | 21.18 | 19.55 | 32 | 18140 | 293398 | 63177452 |
| Coprolalia | 21.01 | 19.55 | 4 | 18168 | 23 | 63470827 |
| Drug screen positive | 20.89 | 19.55 | 13 | 18159 | 3616 | 63467234 |
| Thinking abnormal | 20.69 | 19.55 | 20 | 18152 | 10623 | 63460227 |
| Gestational diabetes | 20.66 | 19.55 | 18 | 18154 | 8378 | 63462472 |
| Rash | 20.39 | 19.55 | 87 | 18085 | 560784 | 62910066 |
| Injection site pain | 20.24 | 19.55 | 6 | 18166 | 129794 | 63341056 |
| Hepatic enzyme increased | 20.12 | 19.55 | 17 | 18155 | 202311 | 63268539 |
| Granulocytopenia | 19.98 | 19.55 | 15 | 18157 | 5657 | 63465193 |
| Apathy | 19.94 | 19.55 | 18 | 18154 | 8776 | 63462074 |
| Schizophrenia | 19.91 | 19.55 | 19 | 18153 | 9933 | 63460917 |
| Personality disorder | 19.66 | 19.55 | 15 | 18157 | 5796 | 63465054 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dystonia | 465.86 | 22.26 | 169 | 12949 | 10676 | 34933137 |
| Akathisia | 403.64 | 22.26 | 141 | 12977 | 7968 | 34935845 |
| Antipsychotic drug level below therapeutic | 329.44 | 22.26 | 92 | 13026 | 2455 | 34941358 |
| Therapeutic product effect variable | 309.84 | 22.26 | 87 | 13031 | 2369 | 34941444 |
| Disinhibition | 307.95 | 22.26 | 92 | 13026 | 3134 | 34940679 |
| Neuroleptic malignant syndrome | 307.64 | 22.26 | 145 | 12973 | 17789 | 34926024 |
| Euphoric mood | 307.45 | 22.26 | 105 | 13013 | 5536 | 34938277 |
| Dyskinesia | 302.97 | 22.26 | 154 | 12964 | 22259 | 34921554 |
| Obsessive-compulsive disorder | 297.13 | 22.26 | 102 | 13016 | 5462 | 34938351 |
| Anosognosia | 287.98 | 22.26 | 68 | 13050 | 905 | 34942908 |
| Suicide attempt | 286.91 | 22.26 | 180 | 12938 | 38936 | 34904877 |
| Blood prolactin abnormal | 283.03 | 22.26 | 67 | 13051 | 902 | 34942911 |
| Tardive dyskinesia | 270.19 | 22.26 | 96 | 13022 | 5694 | 34938119 |
| Increased appetite | 246.87 | 22.26 | 96 | 13022 | 7333 | 34936480 |
| Disturbance in social behaviour | 244.57 | 22.26 | 68 | 13050 | 1783 | 34942030 |
| Sedation | 240.02 | 22.26 | 129 | 12989 | 20877 | 34922936 |
| Weight increased | 226.79 | 22.26 | 223 | 12895 | 92810 | 34851003 |
| Sexual dysfunction | 200.77 | 22.26 | 79 | 13039 | 6224 | 34937589 |
| Extrapyramidal disorder | 199.08 | 22.26 | 97 | 13021 | 12783 | 34931030 |
| Metabolic disorder | 188.44 | 22.26 | 68 | 13050 | 4215 | 34939598 |
| Obesity | 169.57 | 22.26 | 87 | 13031 | 12791 | 34931022 |
| Personality change | 144.88 | 22.26 | 59 | 13059 | 5080 | 34938733 |
| Aggression | 131.02 | 22.26 | 112 | 13006 | 38852 | 34904961 |
| Priapism | 129.47 | 22.26 | 54 | 13064 | 4940 | 34938873 |
| Completed suicide | 115.37 | 22.26 | 162 | 12956 | 98006 | 34845807 |
| Electrocardiogram QT prolonged | 114.39 | 22.26 | 106 | 13012 | 40846 | 34902967 |
| Psychotic disorder | 111.39 | 22.26 | 84 | 13034 | 24368 | 34919445 |
| Leukaemia | 106.78 | 22.26 | 46 | 13072 | 4557 | 34939256 |
| Dyslipidaemia | 105.57 | 22.26 | 53 | 13065 | 7435 | 34936378 |
| Suicidal ideation | 102.22 | 22.26 | 99 | 13019 | 40289 | 34903524 |
| Agitation | 101.19 | 22.26 | 116 | 13002 | 57283 | 34886530 |
| Irritability | 99.76 | 22.26 | 79 | 13039 | 24611 | 34919202 |
| Bruxism | 97.24 | 22.26 | 33 | 13085 | 1702 | 34942111 |
| Oppositional defiant disorder | 95.20 | 22.26 | 25 | 13093 | 524 | 34943289 |
| Decreased eye contact | 92.88 | 22.26 | 24 | 13094 | 471 | 34943342 |
| Homicidal ideation | 90.26 | 22.26 | 35 | 13083 | 2647 | 34941166 |
| Blood prolactin increased | 89.01 | 22.26 | 31 | 13087 | 1729 | 34942084 |
| Catatonia | 87.19 | 22.26 | 41 | 13077 | 4984 | 34938829 |
| Therapeutic product effect incomplete | 83.81 | 22.26 | 99 | 13019 | 50442 | 34893371 |
| Hallucination, auditory | 80.14 | 22.26 | 52 | 13066 | 11865 | 34931948 |
| Leukopenia | 78.65 | 22.26 | 107 | 13011 | 62749 | 34881064 |
| Drug ineffective | 77.68 | 22.26 | 357 | 12761 | 456394 | 34487419 |
| Serotonin syndrome | 76.72 | 22.26 | 62 | 13056 | 19871 | 34923942 |
| Oculogyric crisis | 76.62 | 22.26 | 27 | 13091 | 1559 | 34942254 |
| Trismus | 71.53 | 22.26 | 29 | 13089 | 2466 | 34941347 |
| Prescribed overdose | 70.46 | 22.26 | 46 | 13072 | 10601 | 34933212 |
| Delusion | 67.93 | 22.26 | 48 | 13070 | 12587 | 34931226 |
| Schizoaffective disorder | 65.67 | 22.26 | 23 | 13095 | 1304 | 34942509 |
| Toxicity to various agents | 64.66 | 22.26 | 193 | 12925 | 200169 | 34743644 |
| Mania | 62.71 | 22.26 | 41 | 13077 | 9470 | 34934343 |
| Diarrhoea | 61.73 | 22.26 | 35 | 13083 | 389877 | 34553936 |
| Blood glucose increased | 59.61 | 22.26 | 97 | 13021 | 66621 | 34877192 |
| Swollen tongue | 59.55 | 22.26 | 47 | 13071 | 14558 | 34929255 |
| Crying | 55.91 | 22.26 | 32 | 13086 | 5830 | 34937983 |
| Pneumonia | 55.33 | 22.26 | 34 | 13084 | 362593 | 34581220 |
| Psychomotor hyperactivity | 55.10 | 22.26 | 38 | 13080 | 9584 | 34934229 |
| Choreoathetosis | 54.80 | 22.26 | 19 | 13099 | 1045 | 34942768 |
| Paranoia | 53.91 | 22.26 | 41 | 13077 | 12027 | 34931786 |
| Anxiety | 53.13 | 22.26 | 116 | 13002 | 99312 | 34844501 |
| Anaemia | 51.93 | 22.26 | 12 | 13106 | 233323 | 34710490 |
| Speech disorder | 48.77 | 22.26 | 54 | 13064 | 25632 | 34918181 |
| Coordination abnormal | 48.08 | 22.26 | 32 | 13086 | 7612 | 34936201 |
| Dacryostenosis congenital | 46.23 | 22.26 | 9 | 13109 | 43 | 34943770 |
| Parkinsonism | 43.93 | 22.26 | 31 | 13087 | 8107 | 34935706 |
| Abnormal behaviour | 43.16 | 22.26 | 50 | 13068 | 24919 | 34918894 |
| Tic | 42.64 | 22.26 | 19 | 13099 | 2039 | 34941774 |
| Type 2 diabetes mellitus | 41.84 | 22.26 | 40 | 13078 | 15992 | 34927821 |
| Schizophrenia | 39.94 | 22.26 | 30 | 13088 | 8636 | 34935177 |
| Muscle rigidity | 36.87 | 22.26 | 31 | 13087 | 10487 | 34933326 |
| Blood creatine phosphokinase increased | 35.75 | 22.26 | 62 | 13056 | 44795 | 34899018 |
| Granulocytopenia | 35.41 | 22.26 | 25 | 13093 | 6542 | 34937271 |
| Diabetes mellitus | 35.05 | 22.26 | 63 | 13055 | 46810 | 34897003 |
| Tremor | 34.95 | 22.26 | 88 | 13030 | 82499 | 34861314 |
| Affect lability | 34.84 | 22.26 | 20 | 13098 | 3663 | 34940150 |
| Mood altered | 34.76 | 22.26 | 28 | 13090 | 8924 | 34934889 |
| Pruritus | 34.26 | 22.26 | 6 | 13112 | 141975 | 34801838 |
| Anger | 33.59 | 22.26 | 31 | 13087 | 11853 | 34931960 |
| Hypotonia neonatal | 33.03 | 22.26 | 14 | 13104 | 1331 | 34942482 |
| Blood triglycerides increased | 32.61 | 22.26 | 33 | 13085 | 14126 | 34929687 |
| Somnolence | 31.98 | 22.26 | 103 | 13015 | 111013 | 34832800 |
| Torticollis | 31.66 | 22.26 | 13 | 13105 | 1141 | 34942672 |
| Rhabdomyolysis | 31.35 | 22.26 | 75 | 13043 | 68088 | 34875725 |
| Pyrexia | 31.27 | 22.26 | 48 | 13070 | 332965 | 34610848 |
| Cough | 30.92 | 22.26 | 9 | 13109 | 150131 | 34793682 |
| Acute kidney injury | 30.55 | 22.26 | 42 | 13076 | 304946 | 34638867 |
| Off label use | 30.18 | 22.26 | 71 | 13047 | 419453 | 34524360 |
| Grandiosity | 29.76 | 22.26 | 9 | 13109 | 319 | 34943494 |
| Hyperkinesia | 29.36 | 22.26 | 14 | 13104 | 1754 | 34942059 |
| Blunted affect | 28.93 | 22.26 | 9 | 13109 | 351 | 34943462 |
| Feminisation acquired | 28.75 | 22.26 | 6 | 13112 | 43 | 34943770 |
| Insomnia | 28.71 | 22.26 | 95 | 13023 | 103812 | 34840001 |
| Arthralgia | 28.67 | 22.26 | 14 | 13104 | 170027 | 34773786 |
| Overweight | 28.47 | 22.26 | 14 | 13104 | 1876 | 34941937 |
| Disease progression | 27.34 | 22.26 | 4 | 13114 | 108073 | 34835740 |
| Opisthotonus | 26.63 | 22.26 | 9 | 13109 | 458 | 34943355 |
| Product prescribing issue | 26.59 | 22.26 | 14 | 13104 | 2165 | 34941648 |
| Death | 26.56 | 22.26 | 70 | 13048 | 397979 | 34545834 |
| Thrombocytopenia | 26.13 | 22.26 | 13 | 13105 | 156234 | 34787579 |
| Overdose | 24.92 | 22.26 | 83 | 13035 | 90976 | 34852837 |
| Bipolar disorder | 24.63 | 22.26 | 16 | 13102 | 3653 | 34940160 |
| Myopathy toxic | 24.63 | 22.26 | 9 | 13109 | 577 | 34943236 |
| Neonatal respiratory depression | 23.48 | 22.26 | 8 | 13110 | 417 | 34943396 |
| Febrile neutropenia | 23.47 | 22.26 | 11 | 13107 | 136838 | 34806975 |
| Thinking abnormal | 23.41 | 22.26 | 19 | 13099 | 6118 | 34937695 |
| Asthenia | 23.32 | 22.26 | 35 | 13083 | 245216 | 34698597 |
| Depressed mood | 22.79 | 22.26 | 32 | 13086 | 19285 | 34924528 |
| Streptococcal infection | 22.47 | 22.26 | 17 | 13101 | 4944 | 34938869 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Blood prolactin abnormal | 1471.77 | 18.92 | 314 | 23490 | 3287 | 79717297 |
| Dystonia | 1411.40 | 18.92 | 435 | 23369 | 20964 | 79699620 |
| Sexual dysfunction | 1355.83 | 18.92 | 339 | 23465 | 7424 | 79713160 |
| Anosognosia | 1240.28 | 18.92 | 275 | 23529 | 3489 | 79717095 |
| Disturbance in social behaviour | 1143.29 | 18.92 | 271 | 23533 | 4699 | 79715885 |
| Sedation | 1048.41 | 18.92 | 439 | 23365 | 51456 | 79669128 |
| Dyskinesia | 1024.12 | 18.92 | 414 | 23390 | 44359 | 79676225 |
| Metabolic disorder | 1001.62 | 18.92 | 276 | 23528 | 8894 | 79711690 |
| Personality change | 914.88 | 18.92 | 263 | 23541 | 9907 | 79710677 |
| Suicide attempt | 760.35 | 18.92 | 407 | 23397 | 82525 | 79638059 |
| Completed suicide | 532.95 | 18.92 | 498 | 23306 | 245269 | 79475315 |
| Neuroleptic malignant syndrome | 528.68 | 18.92 | 225 | 23579 | 27334 | 79693250 |
| Tardive dyskinesia | 503.50 | 18.92 | 168 | 23636 | 10403 | 79710181 |
| Akathisia | 421.61 | 18.92 | 156 | 23648 | 13103 | 79707481 |
| Blood glucose increased | 414.84 | 18.92 | 313 | 23491 | 114662 | 79605922 |
| Extrapyramidal disorder | 385.30 | 18.92 | 170 | 23634 | 22509 | 79698075 |
| Orthostatic hypertension | 285.13 | 18.92 | 63 | 23741 | 782 | 79719802 |
| Parkinsonism | 267.79 | 18.92 | 120 | 23684 | 16464 | 79704120 |
| Metabolic syndrome | 251.32 | 18.92 | 72 | 23732 | 2668 | 79717916 |
| Electrocardiogram QT prolonged | 236.33 | 18.92 | 204 | 23600 | 90182 | 79630402 |
| Suicidal ideation | 211.19 | 18.92 | 178 | 23626 | 76162 | 79644422 |
| Obesity | 205.55 | 18.92 | 129 | 23675 | 34996 | 79685588 |
| Psychotic disorder | 193.30 | 18.92 | 132 | 23672 | 41270 | 79679314 |
| Insurance issue | 176.86 | 18.92 | 66 | 23738 | 5667 | 79714917 |
| Oculogyric crisis | 173.30 | 18.92 | 55 | 23749 | 2897 | 79717687 |
| Diabetes mellitus | 163.72 | 18.92 | 156 | 23648 | 78234 | 79642350 |
| Aggression | 162.26 | 18.92 | 129 | 23675 | 50829 | 79669755 |
| Dyslipidaemia | 162.11 | 18.92 | 76 | 23728 | 11557 | 79709027 |
| Agitation | 147.73 | 18.92 | 165 | 23639 | 99550 | 79621034 |
| Hallucination, auditory | 146.79 | 18.92 | 86 | 23718 | 20607 | 79699977 |
| Blood prolactin increased | 141.59 | 18.92 | 51 | 23753 | 3960 | 79716624 |
| Catatonia | 121.37 | 18.92 | 57 | 23747 | 8699 | 79711885 |
| Adverse drug reaction | 114.34 | 18.92 | 119 | 23685 | 66273 | 79654311 |
| Weight increased | 114.13 | 18.92 | 254 | 23550 | 277132 | 79443452 |
| Decreased eye contact | 112.93 | 18.92 | 30 | 23774 | 835 | 79719749 |
| Oppositional defiant disorder | 108.48 | 18.92 | 26 | 23778 | 471 | 79720113 |
| Posture abnormal | 106.57 | 18.92 | 41 | 23763 | 3825 | 79716759 |
| Drug ineffective | 105.52 | 18.92 | 614 | 23190 | 1080299 | 78640285 |
| Respiratory arrest | 102.42 | 18.92 | 105 | 23699 | 57445 | 79663139 |
| Irritability | 101.66 | 18.92 | 90 | 23714 | 41054 | 79679530 |
| Impulse-control disorder | 99.80 | 18.92 | 32 | 23772 | 1742 | 79718842 |
| Delusion | 99.77 | 18.92 | 67 | 23737 | 20356 | 79700228 |
| Antipsychotic drug level below therapeutic | 97.91 | 18.92 | 29 | 23775 | 1209 | 79719375 |
| Diarrhoea | 97.08 | 18.92 | 73 | 23731 | 880416 | 78840168 |
| Mania | 89.43 | 18.92 | 60 | 23744 | 18200 | 79702384 |
| Anxiety | 88.39 | 18.92 | 215 | 23589 | 248297 | 79472287 |
| Bruxism | 87.62 | 18.92 | 36 | 23768 | 3990 | 79716594 |
| Galactorrhoea | 87.59 | 18.92 | 35 | 23769 | 3611 | 79716973 |
| Psychomotor hyperactivity | 86.47 | 18.92 | 57 | 23747 | 16792 | 79703792 |
| Pneumonia | 83.19 | 18.92 | 47 | 23757 | 660199 | 79060385 |
| Homicidal ideation | 82.40 | 18.92 | 33 | 23771 | 3424 | 79717160 |
| Arthralgia | 82.22 | 18.92 | 34 | 23770 | 571769 | 79148815 |
| Condition aggravated | 82.18 | 18.92 | 331 | 23473 | 500793 | 79219791 |
| Paranoia | 79.11 | 18.92 | 57 | 23747 | 19375 | 79701209 |
| Priapism | 73.98 | 18.92 | 33 | 23771 | 4472 | 79716112 |
| Type 2 diabetes mellitus | 73.58 | 18.92 | 88 | 23716 | 57034 | 79663550 |
| Disinhibition | 73.21 | 18.92 | 28 | 23776 | 2570 | 79718014 |
| Cardio-respiratory arrest | 71.02 | 18.92 | 121 | 23683 | 108389 | 79612195 |
| Serotonin syndrome | 70.93 | 18.92 | 77 | 23727 | 44950 | 79675634 |
| Euphoric mood | 70.81 | 18.92 | 38 | 23766 | 7688 | 79712896 |
| Cardiac arrest | 70.00 | 18.92 | 157 | 23647 | 171939 | 79548645 |
| Pain | 69.28 | 18.92 | 65 | 23739 | 703737 | 79016847 |
| Therapeutic product effect variable | 68.87 | 18.92 | 25 | 23779 | 1984 | 79718600 |
| Trismus | 67.88 | 18.92 | 33 | 23771 | 5434 | 79715150 |
| Depression | 67.09 | 18.92 | 178 | 23626 | 216612 | 79503972 |
| Hyperprolactinaemia | 66.53 | 18.92 | 31 | 23773 | 4645 | 79715939 |
| Overdose | 65.04 | 18.92 | 159 | 23645 | 184047 | 79536537 |
| Obsessive-compulsive disorder | 62.44 | 18.92 | 32 | 23772 | 5895 | 79714689 |
| Granulocytopenia | 61.90 | 18.92 | 40 | 23764 | 11391 | 79709193 |
| Joint swelling | 61.72 | 18.92 | 7 | 23797 | 288639 | 79431945 |
| Insomnia | 60.01 | 18.92 | 185 | 23619 | 244985 | 79475599 |
| Personality change due to a general medical condition | 59.81 | 18.92 | 14 | 23790 | 228 | 79720356 |
| Toxicity to various agents | 59.36 | 18.92 | 266 | 23538 | 421274 | 79299310 |
| Tremor | 59.18 | 18.92 | 146 | 23658 | 169937 | 79550647 |
| Pyrexia | 58.58 | 18.92 | 70 | 23734 | 678639 | 79041945 |
| Muscle rigidity | 58.31 | 18.92 | 48 | 23756 | 19834 | 79700750 |
| Increased appetite | 57.79 | 18.92 | 39 | 23765 | 11939 | 79708645 |
| Peripheral swelling | 56.50 | 18.92 | 7 | 23797 | 269610 | 79450974 |
| Infusion related reaction | 56.42 | 18.92 | 3 | 23801 | 230234 | 79490350 |
| Rhabdomyolysis | 55.96 | 18.92 | 106 | 23698 | 103025 | 79617559 |
| Anaemia | 55.50 | 18.92 | 32 | 23772 | 444983 | 79275601 |
| Torsade de pointes | 55.34 | 18.92 | 46 | 23758 | 19266 | 79701318 |
| Abnormal behaviour | 55.13 | 18.92 | 61 | 23743 | 36360 | 79684224 |
| Substance abuse | 54.96 | 18.92 | 36 | 23768 | 10490 | 79710094 |
| Mental disorder | 50.12 | 18.92 | 54 | 23750 | 31248 | 79689336 |
| Cough | 49.22 | 18.92 | 24 | 23780 | 366765 | 79353819 |
| Choreoathetosis | 48.14 | 18.92 | 18 | 23786 | 1552 | 79719032 |
| Intentional overdose | 48.00 | 18.92 | 101 | 23703 | 105859 | 79614725 |
| Blood triglycerides increased | 47.97 | 18.92 | 44 | 23760 | 20996 | 79699588 |
| Rheumatoid arthritis | 47.32 | 18.92 | 4 | 23800 | 208466 | 79512118 |
| Nausea | 47.03 | 18.92 | 139 | 23665 | 957057 | 78763527 |
| Coma | 46.83 | 18.92 | 97 | 23707 | 100552 | 79620032 |
| Rapid eye movement sleep behaviour disorder | 46.13 | 18.92 | 13 | 23791 | 453 | 79720131 |
| Abdominal pain | 44.46 | 18.92 | 31 | 23773 | 389538 | 79331046 |
| Off label use | 44.36 | 18.92 | 132 | 23672 | 907083 | 78813501 |
| Nasopharyngitis | 43.64 | 18.92 | 11 | 23793 | 253870 | 79466714 |
| Coordination abnormal | 43.01 | 18.92 | 38 | 23766 | 17274 | 79703310 |
| Swollen tongue | 42.81 | 18.92 | 58 | 23746 | 42512 | 79678072 |
| Malaise | 42.77 | 18.92 | 50 | 23754 | 489819 | 79230765 |
| General physical health deterioration | 41.75 | 18.92 | 15 | 23789 | 275223 | 79445361 |
| Arthropathy | 41.31 | 18.92 | 3 | 23801 | 177108 | 79543476 |
| Blood creatine phosphokinase increased | 41.00 | 18.92 | 72 | 23732 | 66018 | 79654566 |
| Abdominal discomfort | 40.96 | 18.92 | 12 | 23792 | 250715 | 79469869 |
| Torticollis | 40.85 | 18.92 | 18 | 23786 | 2369 | 79718215 |
| Exposure via ingestion | 40.67 | 18.92 | 23 | 23781 | 5151 | 79715433 |
| Schizoaffective disorder | 39.34 | 18.92 | 17 | 23787 | 2135 | 79718449 |
| Grandiosity | 38.90 | 18.92 | 12 | 23792 | 575 | 79720009 |
| Speech disorder | 38.66 | 18.92 | 63 | 23741 | 54382 | 79666202 |
| Pain in extremity | 37.78 | 18.92 | 32 | 23772 | 364506 | 79356078 |
| Pruritus | 36.94 | 18.92 | 38 | 23766 | 394610 | 79325974 |
| Somnolence | 36.77 | 18.92 | 155 | 23649 | 238826 | 79481758 |
| Mood altered | 36.23 | 18.92 | 35 | 23769 | 17812 | 79702772 |
| Alopecia | 36.13 | 18.92 | 12 | 23792 | 231343 | 79489241 |
| Thrombocytopenia | 36.11 | 18.92 | 17 | 23787 | 265242 | 79455342 |
| Febrile neutropenia | 36.04 | 18.92 | 12 | 23792 | 230987 | 79489597 |
| Restlessness | 36.04 | 18.92 | 56 | 23748 | 46436 | 79674148 |
| Distributive shock | 35.72 | 18.92 | 17 | 23787 | 2670 | 79717914 |
| Crying | 35.57 | 18.92 | 39 | 23765 | 23004 | 79697580 |
| Dyspnoea | 35.49 | 18.92 | 134 | 23670 | 856891 | 78863693 |
| Hyperkinesia | 35.47 | 18.92 | 17 | 23787 | 2712 | 79717872 |
| Rabbit syndrome | 35.36 | 18.92 | 10 | 23794 | 353 | 79720231 |
| Reduced facial expression | 35.26 | 18.92 | 17 | 23787 | 2748 | 79717836 |
| Fatigue | 34.96 | 18.92 | 151 | 23653 | 929576 | 78791008 |
| Schizophrenia | 34.63 | 18.92 | 32 | 23772 | 15408 | 79705176 |
| Cognitive disorder | 34.42 | 18.92 | 69 | 23735 | 69857 | 79650727 |
| Tic | 34.02 | 18.92 | 17 | 23787 | 2969 | 79717615 |
| Haemoglobin decreased | 33.85 | 18.92 | 12 | 23792 | 222107 | 79498477 |
| Infection | 33.66 | 18.92 | 15 | 23789 | 241697 | 79478887 |
| Renal impairment | 33.27 | 18.92 | 4 | 23800 | 157779 | 79562805 |
| COVID-19 | 33.24 | 18.92 | 4 | 23800 | 157670 | 79562914 |
| Symptom recurrence | 31.87 | 18.92 | 15 | 23789 | 2299 | 79718285 |
| Intentional product use issue | 31.73 | 18.92 | 4 | 23800 | 152108 | 79568476 |
| Disease progression | 31.65 | 18.92 | 8 | 23796 | 184354 | 79536230 |
| Swelling | 30.89 | 18.92 | 13 | 23791 | 216698 | 79503886 |
| Affect lability | 30.57 | 18.92 | 26 | 23778 | 11233 | 79709351 |
| Headache | 29.85 | 18.92 | 98 | 23706 | 653674 | 79066910 |
| Sinusitis | 29.05 | 18.92 | 11 | 23793 | 195490 | 79525094 |
| Posturing | 28.42 | 18.92 | 11 | 23793 | 1042 | 79719542 |
| Gastrointestinal haemorrhage | 28.24 | 18.92 | 5 | 23799 | 147714 | 79572870 |
| Stomatitis | 27.99 | 18.92 | 5 | 23799 | 146752 | 79573832 |
| Acute kidney injury | 27.96 | 18.92 | 72 | 23732 | 519332 | 79201252 |
| Tachyphrenia | 27.16 | 18.92 | 13 | 23791 | 2067 | 79718517 |
| Mental status changes | 27.09 | 18.92 | 61 | 23743 | 66898 | 79653686 |
| Thinking abnormal | 27.07 | 18.92 | 26 | 23778 | 13135 | 79707449 |
| Asthenia | 26.73 | 18.92 | 72 | 23732 | 511617 | 79208967 |
| Erythema | 26.48 | 18.92 | 17 | 23787 | 223273 | 79497311 |
| Anger | 26.41 | 18.92 | 29 | 23775 | 17133 | 79703451 |
| Overweight | 26.18 | 18.92 | 16 | 23788 | 4134 | 79716450 |
| Rash | 26.18 | 18.92 | 87 | 23717 | 578271 | 79142313 |
| Stereotypy | 25.97 | 18.92 | 10 | 23794 | 935 | 79719649 |
| Injection site pain | 25.70 | 18.92 | 4 | 23800 | 129834 | 79590750 |
| Feminisation acquired | 25.59 | 18.92 | 5 | 23799 | 32 | 79720552 |
| Maternal exposure during pregnancy | 25.29 | 18.92 | 5 | 23799 | 136533 | 79584051 |
| Bradypnoea | 25.19 | 18.92 | 18 | 23786 | 6034 | 79714550 |
| Sepsis | 25.13 | 18.92 | 26 | 23778 | 269402 | 79451182 |
| Spasmodic dysphonia | 24.13 | 18.92 | 7 | 23797 | 271 | 79720313 |
| Systemic lupus erythematosus | 23.38 | 18.92 | 4 | 23800 | 121145 | 79599439 |
| Drooling | 23.22 | 18.92 | 17 | 23787 | 5917 | 79714667 |
| Contraindicated product administered | 23.18 | 18.92 | 9 | 23795 | 157529 | 79563055 |
| Hallucination | 23.11 | 18.92 | 67 | 23737 | 85678 | 79634906 |
| Treatment failure | 23.08 | 18.92 | 11 | 23793 | 170475 | 79550109 |
| Drug screen positive | 22.89 | 18.92 | 17 | 23787 | 6046 | 79714538 |
| Treatment noncompliance | 22.70 | 18.92 | 49 | 23755 | 52219 | 79668365 |
| Sperm concentration decreased | 22.34 | 18.92 | 5 | 23799 | 66 | 79720518 |
| Corneal reflex decreased | 22.17 | 18.92 | 7 | 23797 | 362 | 79720222 |
| Wound | 22.06 | 18.92 | 4 | 23800 | 116175 | 79604409 |
| Decreased appetite | 22.06 | 18.92 | 43 | 23761 | 342375 | 79378209 |
| Echolalia | 21.94 | 18.92 | 7 | 23797 | 375 | 79720209 |
| Sinus bradycardia | 21.82 | 18.92 | 32 | 23772 | 25215 | 79695369 |
| Depressed mood | 21.69 | 18.92 | 46 | 23758 | 48434 | 79672150 |
| Back pain | 21.56 | 18.92 | 36 | 23768 | 304144 | 79416440 |
| Abdominal pain upper | 21.55 | 18.92 | 21 | 23783 | 223798 | 79496786 |
| Product prescribing issue | 21.52 | 18.92 | 14 | 23790 | 4031 | 79716553 |
| Ventricular arrhythmia | 21.15 | 18.92 | 19 | 23785 | 8821 | 79711763 |
| Myopathy toxic | 21.14 | 18.92 | 9 | 23795 | 1089 | 79719495 |
| Interstitial lung disease | 21.12 | 18.92 | 4 | 23800 | 112596 | 79607988 |
| Vomiting | 20.98 | 18.92 | 115 | 23689 | 665713 | 79054871 |
| Cardiac failure | 20.94 | 18.92 | 10 | 23794 | 154832 | 79565752 |
| Obsessive thoughts | 20.88 | 18.92 | 9 | 23795 | 1123 | 79719461 |
| Blister | 20.86 | 18.92 | 5 | 23799 | 119471 | 79601113 |
| Pressure of speech | 20.18 | 18.92 | 9 | 23795 | 1219 | 79719365 |
| Diabetic coma | 20.02 | 18.92 | 9 | 23795 | 1242 | 79719342 |
| Muscle contractions involuntary | 19.95 | 18.92 | 13 | 23791 | 3752 | 79716832 |
| Infarction | 19.93 | 18.92 | 14 | 23790 | 4568 | 79716016 |
| Drug intolerance | 19.90 | 18.92 | 30 | 23774 | 264089 | 79456495 |
| Influenza | 19.74 | 18.92 | 7 | 23797 | 129599 | 79590985 |
| Mobility decreased | 19.66 | 18.92 | 6 | 23798 | 122169 | 79598415 |
| Urticaria | 19.48 | 18.92 | 16 | 23788 | 185185 | 79535399 |
| Bipolar disorder | 19.31 | 18.92 | 17 | 23787 | 7690 | 79712894 |
| Weight decreased | 19.27 | 18.92 | 49 | 23755 | 355149 | 79365435 |
| Streptococcal infection | 19.22 | 18.92 | 18 | 23786 | 8812 | 79711772 |
| Poisoning | 18.97 | 18.92 | 30 | 23774 | 25242 | 79695342 |
FDA Adverse Event Reporting System (Pediatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dacryostenosis congenital | 39.35 | 29.74 | 8 | 117 | 8 | 89659 |
| Opisthotonus | 35.79 | 29.74 | 8 | 117 | 17 | 89650 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AE04 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Indole derivatives |
| FDA EPC | N0000175430 | Atypical Antipsychotic |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D018490 | Serotonin Agents |
| MeSH PA | D012702 | Serotonin Antagonists |
| MeSH PA | D014149 | Tranquilizing Agents |
| CHEBI has role | CHEBI:35471 | psychotropic drugs |
| CHEBI has role | CHEBI:35476 | neuroleptics |
| CHEBI has role | CHEBI:37956 | antihistamines |
| CHEBI has role | CHEBI:48279 | serotonin antagonists |
| CHEBI has role | CHEBI:48561 | dopaminergic antagonists |
| CHEBI has role | CHEBI:48876 | muscarinic antagonists |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Mixed bipolar I disorder | indication | 16506000 | DOID:3312 |
| Schizophrenia | indication | 58214004 | DOID:5419 |
| Bipolar disorder in remission | indication | 85248005 | |
| Bipolar affective disorder, current episode manic | indication | 191618007 | |
| Agitation associated with Schizophrenia | indication | ||
| Bipolar affective disorder, current episode depression | off-label use | 191627008 | DOID:3312 |
| Depression Treatment Adjunct | off-label use | ||
| Tachyarrhythmia | contraindication | 6285003 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
| Senile dementia | contraindication | 15662003 | |
| Agranulocytosis | contraindication | 17182001 | DOID:12987 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Hypovolemia | contraindication | 28560003 | |
| Orthostatic hypotension | contraindication | 28651003 | |
| Torsades de pointes | contraindication | 31722008 | |
| Dehydration | contraindication | 34095006 | |
| Dysphagia | contraindication | 40739000 | |
| Hypokalemia | contraindication | 43339004 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Bradycardia | contraindication | 48867003 | |
| Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
| Hepatic failure | contraindication | 59927004 | |
| Cerebrovascular disease | contraindication | 62914000 | DOID:6713 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Extrapyramidal disease | contraindication | 76349003 | |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Heart failure | contraindication | 84114007 | DOID:6000 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Tardive dyskinesia | contraindication | 102449007 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Hypomagnesemia | contraindication | 190855004 | |
| Decompensated cardiac failure | contraindication | 195111005 | |
| Metabolic syndrome X | contraindication | 237602007 | DOID:14221 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Severe diarrhea | contraindication | 409587002 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Acquired torsion dystonia | contraindication | 433493000 | |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Carcinoma of female breast | contraindication | 447782002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.26 | acidic |
| pKa2 | 7.35 | Basic |
| pKa3 | 0.27 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 20MG BASE | GEODON | VIATRIS | N020825 | Feb. 5, 2001 | RX | CAPSULE | ORAL | Jan. 28, 2025 | INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES |
| EQ 40MG BASE | GEODON | VIATRIS | N020825 | Feb. 5, 2001 | RX | CAPSULE | ORAL | Jan. 28, 2025 | INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES |
| EQ 60MG BASE | GEODON | VIATRIS | N020825 | Feb. 5, 2001 | RX | CAPSULE | ORAL | Jan. 28, 2025 | INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES |
| EQ 80MG BASE | GEODON | VIATRIS | N020825 | Feb. 5, 2001 | RX | CAPSULE | ORAL | Jan. 28, 2025 | INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.32 | WOMBAT-PK | CHEMBL | |||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 9.40 | WOMBAT-PK | CHEMBL | |||
| Beta-2 adrenergic receptor | GPCR | Ki | 5.30 | PDSP | |||||
| D(1A) dopamine receptor | GPCR | Ki | 8.02 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.30 | WOMBAT-PK | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 6.92 | WOMBAT-PK | |||||
| Sodium-dependent serotonin transporter | Transporter | IC50 | 7 | WOMBAT-PK | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 7.36 | PDSP | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | EC50 | 8.47 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.57 | PDSP | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | ANTAGONIST | Ki | 8.89 | WOMBAT-PK | ||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 7.22 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | Ki | 8.30 | WOMBAT-PK | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 8 | WOMBAT-PK | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 7.32 | PDSP | |||||
| D(3) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.14 | WOMBAT-PK | ||||
| D(1B) dopamine receptor | GPCR | Ki | 6.82 | PDSP | |||||
| Histamine H1 receptor | GPCR | Ki | 7.33 | WOMBAT-PK | |||||
| Histamine H2 receptor | GPCR | Ki | 5.46 | PDSP | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.55 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.52 | PDSP | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5 | PDSP | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.80 | PDSP | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 5.80 | PDSP | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | Ki | 8.70 | WOMBAT-PK | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 7.11 | PDSP | |||||
| Sodium-dependent dopamine transporter | Transporter | WOMBAT-PK | |||||||
| D(4) dopamine receptor | GPCR | ANTAGONIST | Ki | 7.30 | WOMBAT-PK | ||||
| 5-hydroxytryptamine receptor 3A | Ion channel | Ki | 6.40 | WOMBAT-PK | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 8.05 | PDSP | |||||
| 5-hydroxytryptamine receptor 5A | GPCR | Ki | 6.54 | PDSP | |||||
| 5-hydroxytryptamine receptor 1E | GPCR | Ki | 6.44 | WOMBAT-PK | |||||
| Aspartate aminotransferase, cytoplasmic | Enzyme | IC50 | 5.27 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 8.30 | IUPHAR | ||||
| Histone H1.0 | Nuclear other | Ki | 7.82 | CHEMBL | |||||
| Beta-1 adrenergic receptor | GPCR | Ki | 5.59 | PDSP | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 9.30 | CHEMBL | |||||
| Histamine H1 receptor | GPCR | Ki | 7.80 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Ki | 8.32 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 9.38 | CHEMBL | |||||
| Histamine H1 receptor | GPCR | IC50 | 6.82 | CHEMBL | |||||
| Transporter | Transporter | Ki | 7.32 | CHEMBL | |||||
| Adrenergic receptor alpha-1 | GPCR | Ki | 7.96 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021249 | VUID |
| N0000148690 | NUI |
| D02100 | KEGG_DRUG |
| 138982-67-9 | SECONDARY_CAS_RN |
| 199191-69-0 | SECONDARY_CAS_RN |
| 4021249 | VANDF |
| 4030214 | VANDF |
| 4030215 | VANDF |
| C0380393 | UMLSCUI |
| CHEBI:10119 | CHEBI |
| CHEMBL708 | ChEMBL_ID |
| CHEMBL1375743 | ChEMBL_ID |
| CHEMBL1712 | ChEMBL_ID |
| CHEMBL3989833 | ChEMBL_ID |
| CHEMBL1200997 | ChEMBL_ID |
| DB00246 | DRUGBANK_ID |
| C092292 | MESH_SUPPLEMENTAL_RECORD_UI |
| 60854 | PUBCHEM_CID |
| 59 | IUPHAR_LIGAND_ID |
| 7155 | INN_ID |
| 6UKA5VEJ6X | UNII |
| 115698 | RXNORM |
| 16791 | MMSL |
| 187736 | MMSL |
| 331404 | MMSL |
| 41113 | MMSL |
| d04747 | MMSL |
| 009104 | NDDF |
| 009105 | NDDF |
| 009579 | NDDF |
| 129479007 | SNOMEDCT_US |
| 373389002 | SNOMEDCT_US |
| 409356003 | SNOMEDCT_US |
| 409357007 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0052 | CAPSULE | 20 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0052 | CAPSULE | 20 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0052 | CAPSULE | 20 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0054 | CAPSULE | 40 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0054 | CAPSULE | 40 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0054 | CAPSULE | 40 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0056 | CAPSULE | 60 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0056 | CAPSULE | 60 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0056 | CAPSULE | 60 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0058 | CAPSULE | 80 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0058 | CAPSULE | 80 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0058 | CAPSULE | 80 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0352 | CAPSULE | 20 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0352 | CAPSULE | 20 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0352 | CAPSULE | 20 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0354 | CAPSULE | 40 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0354 | CAPSULE | 40 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0354 | CAPSULE | 40 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0356 | CAPSULE | 60 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0356 | CAPSULE | 60 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0356 | CAPSULE | 60 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0358 | CAPSULE | 80 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0358 | CAPSULE | 80 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-0358 | CAPSULE | 80 mg | ORAL | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-1203 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 30 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-1203 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 30 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-3920 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-3920 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-3920 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 32 sections |
| Geodon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0049-3960 | CAPSULE | 20 mg | ORAL | NDA | 32 sections |